Navigating Choices: A Questionnaire-based Study on Usage of Antiplatelet Therapies in Management of Acute Coronary Syndrome in India

Authors

  • Dr PRAFULLA KERKAR Consultant Interventional Cardiologist, Asian Heart Institute, Mumbai, Maharashtra, India
  • Dr JAYESH PRAJAPATI Interventional Cardiologist, Apollo Hospital International Limited, Ahmedabad, Gujarat, India
  • Dr PK SAHOO Senior Consultant Cardiologist and Director of Interventional Cardiology, Apollo Hospitals, Bhubaneswar, Odisha, India
  • Dr PANKAJ RASTOGI Consultant Cardiologist, Divya Heart Clinic, Lucknow, Uttar Pradesh, India
  • Dr SUNIP BANERJEE¥ Interventional Cardiologist, Kolkata Heart Lung Centre, Kolkata, West Bengal, India
  • Dr SAUMITRA RAY Senior Interventional Cardiologist and Director of Invasive Cardiology, AMRI Hospitals, Kolkata, West Bengal, India
  • Dr BHUPEN DESAI Consultant Interventional Cardiologist, Desai Heart Care Clinic, Mumbai, Maharashtra, India
  • Dr SUNIL SATHE Senior Interventional Cardiologist, Cardiac Care and Counseling Center, Pune, Maharashtra, India
  • Dr JOHANN CHRISTOPHER onsultant - Interventional Cardiology and Cardiac Imaging, CARE Hospitals, Hyderabad, Telangana, India
  • Dr NARAYANA MURTHY Consultant Interventional Cardiologist, Sagar Hospitals, Bengaluru, Karnataka, India
  • Dr CHETAN SHAH Consultant Interventional Cardiologist, Sagar Hospitals, Bengaluru, Karnataka, India
  • Dr MAYUR MAYABHATE Medical Affairs, Alkem Laboratories Ltd., Mumbai, Maharashtra, India
  • Dr JESSICA DALI Interventional Cardiologist, Zynova Heart Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.59793/ijcp.v34i12.1003

Keywords:

Percutaneous coronary intervention,, acute coronary syndrome,, dual antiplatelet therapy, ticagrelor

Abstract

Percutaneous coronary intervention (PCI) is a common invasive cardiac procedure used to treat acute coronary
syndrome (ACS). The main objective of anticoagulant therapy in PCI is to minimize the risk of plaque rupture and decrease
the formation of blood clots. Understanding clinicians' prescription patterns is crucial for optimizing treatment strategies
for patients with ACS who have undergone PCI. Methods: It was a cross-sectional, questionnaire-based, noninterventional
study which included questionnaire responses from 136 cardiologists, regarding usage of antiplatelets in ACS management.
Results: Ticagrelor and aspirin dual antiplatelet therapy (DAPT) is favored by 54% cardiologists in managing ACS patients
who have undergone PCI, regardless of the presence or absence of type 2 diabetes mellitus (T2DM). Further, 78% of the
participants preferred long-term DAPT over short-term and medium-term alternatives. Forty percent respondents preferred
a 1-month triple antithrombotic therapy (TAT) for PCI patients with atrial fibrillation. Additionally, the study emphasized
the importance of considering factors like age, bleeding history, hemoglobin, and creatinine clearance in determining the
optimal antithrombotic strategy. Conclusion: This study contributes valuable insights into the real-world practices of health
care practitioners, paving the way for more informed and personalized ACS management strategies in Indian patients.

Downloads

Published

2024-06-03

Issue

Section

Research Review

How to Cite

Navigating Choices: A Questionnaire-based Study on Usage of Antiplatelet Therapies in Management of Acute Coronary Syndrome in India . (2024). Indian Journal Of Clinical Practice, 34(12), 14-20. https://doi.org/10.59793/ijcp.v34i12.1003

Similar Articles

11-20 of 130

You may also start an advanced similarity search for this article.